ImmuCell Corporation Accrued Liabilities for Commissions, Expense and Taxes
ImmuCell Corporation (ICCC) had Accrued Liabilities for Commissions, Expense and Taxes of $150.00 thousand as of 2023-06-30, per its 10-Q filed 2023-08-10.
Discontinued › Notes › Insurance
us-gaap:AccruedLiabilitiesForCommissionsExpenseAndTaxes · last filed 2023-08-10
- 2023-06-30: Accrued Liabilities for Commissions, Expense and Taxes $150.00K.
- 2022-12-31: Accrued Liabilities for Commissions, Expense and Taxes $100.00K.
| Period end | Accrued Liabilities for Commissions, Expense and Taxes |
|---|---|
| 2023-06-30 | $150.00K 10-Q · filed 2023-08-10 |
| 2022-12-31 | $100.00K 10-Q · filed 2023-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |